Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "RAT"

7942 News Found

India’s healthcare and pharma sectors recorded a total of 72 transactions valued at US$ 3.5 billion in Q3 2025: Grant Thornton Bharat
News | October 31, 2025

India’s healthcare and pharma sectors recorded a total of 72 transactions valued at US$ 3.5 billion in Q3 2025: Grant Thornton Bharat

The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million


Allergan Aesthetics and Girls inspire the next generation of women leaders in STEM
News | October 30, 2025

Allergan Aesthetics and Girls inspire the next generation of women leaders in STEM

Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives


Orion secures license to Abzena’s next-generation cancer antibody
R&D | October 29, 2025

Orion secures license to Abzena’s next-generation cancer antibody

The antibody was designed and developed at Abzena’s Cambridge, UK,


Dr Reddys Laboratories reports Q2 FY26 consolidated PAT at Rs. 1,437.2 Cr
News | October 27, 2025

Dr Reddys Laboratories reports Q2 FY26 consolidated PAT at Rs. 1,437.2 Cr

Dr Reddys Laboratories has reported total income of Rs. 8,805.1 crore during the period ended September 30, 2025


ANRF, in collaboration with ICMR and Gates Foundation, launches Maha MedTech Mission
R&D | October 27, 2025

ANRF, in collaboration with ICMR and Gates Foundation, launches Maha MedTech Mission

With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market


Merck KGaA reports long-term OGSIVEO phase 3 data demonstrating sustained efficacy and safety in desmoid tumors
Clinical Trials | October 25, 2025

Merck KGaA reports long-term OGSIVEO phase 3 data demonstrating sustained efficacy and safety in desmoid tumors

Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile


Johnson & Johnson’s Rybrevant shows 45% response rate in HNSCC
Clinical Trials | October 22, 2025

Johnson & Johnson’s Rybrevant shows 45% response rate in HNSCC

Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab


Gujarat Themis Biosyn doubles fermentation production capacity at Vapi
News | October 19, 2025

Gujarat Themis Biosyn doubles fermentation production capacity at Vapi

With this expansion, the overall fermentation capacity of the company has increased from 450 KL to 990 KL


IKS Health announces generative AI platform built on Google cloud
Digitisation | October 18, 2025

IKS Health announces generative AI platform built on Google cloud

IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow